Clostridium Difficile
Morphology |
A gram positive rod that is anaerobic, motile, capable of producing subterminal spores,
and produces a cytotoxin and enterotoxin.
|
---|---|
Disease |
Antibiotic - associated diarrhea, pseudomembranous colitis (PMC).
|
Zoonosis |
Potential zoonosis. Moreover, contaminated food can cause infection.
|
Host Range |
Humans and animals.
|
---|---|
Modes of Transmission |
Fecal-oral contact; evidence for transmission via fomites and hands exists.
|
Signs and Symptoms |
Mild or moderate diarrhea, pseudomembranous colitis, may be associated with the passage
of mucus or occult blood in stool, fever, cramping abdominal discomfort and peripheral
leukocytosis are common but found in fewer than half the patients.
|
Infectious Dose | unknown |
Incubation Period |
unknown
|
Prophylaxis | None available. |
---|---|
Vaccines | None available. |
Treatment |
Antibiotic therapy. Oral therapy with metronidazole or vancomycin.
|
Surveillance |
Diagnosed by PCR. Monitor for symptoms (loose stool). Recover C. difficile organisms
and/or toxin from stool samples to confirm.
|
MSU Requirements | Report any exposures. |
Laboratory Acquired Infections (LAIs) | One reported case of an LAI from C. difficile.
|
---|---|
Sources |
Clinical specimens (feces). Cultures, frozen stocks, other samples described in IBC
protocol.
|
Canadian MSDS: | http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/index-eng.php |
---|---|
BMBL
|
https://www.cdc.gov/labs/bmbl/?CDC_AAref_Val=https://www.cdc.gov/labs/BMBL.html |
CDC | |
NIH Guidelines |
Risk Group 2
|
Agents that are associated with human disease which is rarely serious and for which preventive or therapeutic interventions are often available. |
---|---|
BSL2
|
For all procedures involving suspected or known infectious specimen or cultures.
|
ABSL2
|
For all procedures utilizing infected animals.
|
Small
|
Notify others working in the lab. Remove PPE and don new PPE. Cover area of the spill
with absorbent material and add fresh 1:10 bleach:water. Allow 20 munutes (or as directed)
of contact time. After 20 minutes, cleanup and dispose of materials.
|
---|---|
Large
|
|
Mucous membrane
|
Flush eyes, mouth, or nose for 5 minutes at eyewash station.
|
---|---|
Other Exposures
|
Wash area with soap and water for 5 minutes.
|
Reporting |
Immediately report incident to supervisor, complete a First Report of Injury form, and submit to Safety and Risk Management.
|
Medical Follow-up
|
During business hours: Bridger Occupational Health 3406 Laramie Drive. Weekdays 8am -6pm. Weekends 9am-5pm
After business hours: Bozeman Deaconess Hospital Emergency Room 915 Highland Blvd Bozeman, MT |
Disinfection |
Spores are susceptible to 1:10 bleach:water for 20 minutes; susceptible to >2% gluteraldehyde
with minimum of 20 minutes contact time, accelerated hydrogen peroxide
|
---|---|
Inactivation |
Inactivated by moist heat (121oC for 30 minutes)
|
Survival Outside Host |
Can survive in soil, meat, and vegetables. Spores can survive for long periods outside of host. |
Minimum PPE Requirements
|
Lab coat, disposable gloves, safety glasses, closed toed shoes, long pants
|
---|---|
Additional Precautions
|
Additioanl PPE may be required depending on lab specific SOPs and IBC Protocol. |